XSHE
002287
Market cap1.69bUSD
Jul 10, Last price
20.04CNY
1D
0.30%
1Q
-14.10%
Jan 2017
-41.25%
IPO
19.43%
Name
Tibet Cheezheng Tibetan Med Co Ltd
Chart & Performance
P/E
17.74
P/S
4.75
EPS
1.13
Div Yield, %
4.10%
Shrs. gr., 5y
0.54%
Rev. gr., 5y
6.41%
Revenues
2.42b
+3.34%
Net income
646m
+10.98%
CFO
730m
+59.76%
Dividend
Sep 22, 20250.22 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Tibet Cheezheng Tibetan Medicine Co., Ltd., along with its affiliated entities, specializes in the entire lifecycle of traditional Tibetan pharmaceuticals, from their research and development to manufacturing and distribution across China. The company's diverse range of drug products addresses various medical conditions, including those impacting the cardiovascular, respiratory, digestive, nervous, and musculoskeletal systems, as well as urinary, reproductive, and gynecological health. Established in 1995, the firm is headquartered in Nyingchi, China, and operates as a subsidiary of Gansu Qizheng Industry Group Co., Ltd.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2019‑00 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||||
Revenues | |||||||||||||
Cost of revenue | |||||||||||||
Unusual Expense (Income) | |||||||||||||
NOPBT | |||||||||||||
NOPBT Margin | |||||||||||||
Operating Taxes | |||||||||||||
Tax Rate | |||||||||||||
NOPAT | |||||||||||||
Net income | |||||||||||||
Dividends | |||||||||||||
Dividend yield | |||||||||||||
Proceeds from repurchase of equity | |||||||||||||
BB yield | |||||||||||||
| Debt | |||||||||||||
Debt current | |||||||||||||
Long-term debt | |||||||||||||
Deferred revenue | |||||||||||||
Other long-term liabilities | |||||||||||||
Net debt | |||||||||||||
| Cash flow | |||||||||||||
Cash from operating activities | |||||||||||||
CAPEX | |||||||||||||
Cash from investing activities | |||||||||||||
Cash from financing activities | |||||||||||||
FCF | |||||||||||||
| Balance | |||||||||||||
Cash | |||||||||||||
Long term investments | |||||||||||||
Excess cash | |||||||||||||
Stockholders' equity | |||||||||||||
Invested Capital | |||||||||||||
ROIC | |||||||||||||
ROCE | |||||||||||||
| EV | |||||||||||||
Common stock shares outstanding | |||||||||||||
Price | |||||||||||||
Market cap | |||||||||||||
EV | |||||||||||||
EBITDA | |||||||||||||
EV/EBITDA | |||||||||||||
Interest | |||||||||||||
Interest/NOPBT | |||||||||||||